Hill, A. J. et al. Incidence of kidney stones in the United States: the continuous National Health and Nutrition Examination Survey. J. Urol. 207, 851–856 (2022).
Google Scholar
Xu, J. Z. et al. Sex disparities and the risk of urolithiasis: a large cross-sectional study. Ann. Med. 54, 1627–1635 (2022).
Google Scholar
Filler, G. et al. In focus: perplexing increase of urinary stone disease in children, adolescent and young adult women and its economic impact. Front. Med. 10, 1272900 (2023).
Romero, V., Akpinar, H. & Assimos, D. G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev. Urol. 12, e86–e96 (2010).
Google Scholar
Chen, K. W. et al. Trends in kidney stone prevalence among US adults. Can. Urol. Assoc. J. 19, 58–60 (2025).
Google Scholar
Ward, J. B. et al. Pediatric urinary stone disease in the United States: the Urologic Diseases in America project. Urology 129, 180–187 (2019).
Google Scholar
Scales, C. D. Jr., Smith, A. C., Hanley, J. M. & Saigal, C. S. Prevalence of kidney stones in the United States. Eur. Urol. 62, 160–165 (2012).
Google Scholar
Scales, C. D. Jr. et al. Urinary stone disease: advancing knowledge, patient care, and population health. Clin. J. Am. Soc. Nephrol. 11, 1305–1312 (2016).
Google Scholar
Malieckal, D. A. & Goldfarb, D. S. Occupational kidney stones. Curr. Opin. Nephrol. Hypertens. 29, 232–236 (2020).
Google Scholar
New, F. & Somani, B. K. A complete world literature review of quality of life (QOL) in patients with kidney stone disease (KSD). Curr. Urol. Rep. 17, 88 (2016).
Google Scholar
Ferraro, P. M., Curhan, G. C., D’Addessi, A. & Gambaro, G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J. Nephrol. 30, 227–233 (2017).
Google Scholar
Saigal, C. S., Joyce, G. & Timilsina, A. R. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int. 68, 1808–1814 (2005).
Google Scholar
Lotan, Y., Cadeddu, J. A., Roerhborn, C. G., Pak, C. Y. & Pearle, M. S. Cost-effectiveness of medical management strategies for nephrolithiasis. J. Urol. 172, 2275–2281 (2004).
Google Scholar
Bargagli, M. et al. Urinary metabolic profile and stone composition in kidney stone formers with and without heart disease. J. Nephrol. 35, 851–857 (2022).
Google Scholar
Shavit, L. et al. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol. Dial. Transpl. 30, 607–613 (2015).
Shoag, J., Halpern, J., Goldfarb, D. S. & Eisner, B. H. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J. Urol. 192, 1440–1445 (2014).
Google Scholar
Sakhaee, K., Maalouf, N. M., Kumar, R., Pasch, A. & Moe, O. W. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 79, 393–403 (2011).
Google Scholar
Taylor, E. N., Feskanich, D., Paik, J. M. & Curhan, G. C. Nephrolithiasis and risk of incident bone fracture. J. Urol. 195, 1482–1486 (2016).
Google Scholar
Coe, F. L., Evan, A. & Worcester, E. in Seldin and Giebisch’s The Kidney (eds Alpern, R. J. et al.) 2311–2349 (Elsevier, 2013).
Werness, P. G., Brown, C. M., Smith, L. H. & Finlayson, B. EQUIL2: a BASIC computer program for the calculation of urinary saturation. J. Urol. 134, 1242–1244 (1985).
Google Scholar
Parks, J. H., Coward, M. & Coe, F. L. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 51, 894–900 (1997).
Google Scholar
Siener, R., Glatz, S., Nicolay, C. & Hesse, A. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. Eur. Urol. 44, 467–474 (2003).
Google Scholar
Borghi, L. et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N. Engl. J. Med. 346, 77–84 (2002).
Google Scholar
Borghi, L. et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J. Urol. 155, 839–843 (1996).
Google Scholar
Ferraro, P. M. et al. Short-term changes in urinary relative supersaturation predict recurrence of kidney stones: a tool to guide preventive measures in urolithiasis. J. Urol. 200, 1082–1087 (2018).
Google Scholar
Prochaska, M., Taylor, E., Ferraro, P. M. & Curhan, G. Relative supersaturation of 24-hour urine and likelihood of kidney stones. J. Urol. 199, 1262–1266 (2018).
Google Scholar
Pak, C. Y. Citrate and renal calculi. Min. Electrolyte Metab. 13, 257–266 (1987).
Hallson, P. C., Rose, G. A. & Sulaiman, S. Magnesium reduces calcium oxalate crystal formation in human whole urine. Clin. Sci. 62, 17–19 (1982).
Pak, C. Y. & Arnold, L. H. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc. Soc. Exp. Biol. Med. 149, 930–932 (1975).
Google Scholar
Coe, F. L., Lawton, R. L., Goldstein, R. B. & Tembe, V. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc. Soc. Exp. Biol. Med. 149, 926–929 (1975).
Google Scholar
Pak, C. Y. et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J. Clin. Invest. 59, 426–431 (1977).
Google Scholar
Coe, F. L. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int. 13, 418–426 (1978).
Google Scholar
Coe, F. L. Uric acid and calcium oxalate nephrolithiasis. Kidney Int. 24, 392–403 (1983).
Google Scholar
Meyer, J. L., Bergert, J. H. & Smith, L. H. Epitaxial relationships in urolithiasis: the brushite-whewellite system. Clin. Sci. Mol. Med. 52, 143–148 (1977).
Google Scholar
Khan, S. R. & Canales, B. K. Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43, 109–123 (2015).
Google Scholar
Sethmann, I. et al. Microstructures of Randall’s plaques and their interfaces with calcium oxalate monohydrate kidney stones reflect underlying mineral precipitation mechanisms. Urolithiasis 45, 235–248 (2017).
Google Scholar
Khan, S. R., Rodriguez, D. E., Gower, L. B. & Monga, M. Association of Randall plaque with collagen fibers and membrane vesicles. J. Urol. 187, 1094–1100 (2012).
Google Scholar
Verrier, C. et al. Topography, composition and structure of incipient randall plaque at the nanoscale level. J. Urol. 196, 1566–1574 (2016).
Google Scholar
Bourg, S. et al. Confining calcium oxalate crystal growth in a carbonated apatite-coated microfluidic channel to better understand the role of Randall’s plaque in kidney stone formation. Lab. Chip 24, 2017–2024 (2024).
Google Scholar
Robertson, W. G., Peacock, M. & Nordin, B. E. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin. Chim. Acta 43, 31–37 (1973).
Google Scholar
Borofsky, M. S. et al. Integration and utilization of modern technologies in nephrolithiasis research. Nat. Rev. Urol. 13, 549–557 (2016).
Google Scholar
Evan, A. P., Worcester, E. M., Coe, F. L., Williams, J. Jr. & Lingeman, J. E. Mechanisms of human kidney stone formation. Urolithiasis 43, 19–32 (2015).
Google Scholar
Randall, A. The origin and growth of renal calculi. Ann. Surg. 105, 1009 (1937).
Google Scholar
Coe, F. L., Evan, A. P., Worcester, E. M. & Lingeman, J. E. Three pathways for human kidney stone formation. Urol. Res. 38, 147–160 (2010).
Google Scholar
Evan, A. P. et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 69, 2227–2235 (2006).
Google Scholar
Evan, A. P. et al. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int. 71, 795–801 (2007).
Google Scholar
Evan, A. P. et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111, 607–616 (2003).
Google Scholar
Evan, A. P. et al. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat. Rec. 291, 325–334 (2008).
Evan, A. E. et al. Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int. 74, 223–229 (2008).
Google Scholar
Mandel, N., Mandel, I., Fryjoff, K., Rejniak, T. & Mandel, G. Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J. Urol. 169, 2026–2029 (2003).
Google Scholar
Evan, A. P. et al. Mechanism by which shock wave lithotripsy can promote formation of human calcium phosphate stones. Am. J. Physiol. Ren. Physiol. 308, F938–F949 (2015).
Parks, J. H., Coe, F. L., Evan, A. P. & Worcester, E. M. Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol. Dial. Transpl. 24, 130–136 (2009).
Stoller, M. L., Low, R. K., Shami, G. S., McCormick, V. D. & Kerschmann, R. L. High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall’s plaque formation. J. Urol. 156, 1263–1266 (1996).
Google Scholar
Kim, S. C. et al. Stone formation is proportional to papillary surface coverage by Randall’s plaque. J. Urol. 173, 117–119 (2005).
Google Scholar
Evan, A. P., Coe, F. L., Lingeman, J., Bledsoe, S. & Worcester, E. M. Randall’s plaque in stone formers originates in ascending thin limbs. Am. J. Physiol. Ren. Physiol. 315, F1236–F1242 (2018).
Daudon, M., Dore, J. C., Jungers, P. & Lacour, B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol. Res. 32, 241–247 (2004).
Google Scholar
Anderegg, M. A. et al. Prevalence and characteristics of genetic disease in adult kidney stone formers. Nephrol. Dial. Transpl. 39, 1426–1441 (2024).
Prot-Bertoye, C. et al. CKD and its risk factors among patients with cystinuria. Clin. J. Am. Soc. Nephrol. 10, 842–851 (2015).
Google Scholar
Alexander, R. T., Fuster, D. G. & Dimke, H. Mechanisms underlying calcium nephrolithiasis. Annu. Rev. Physiol. 84, 559–583 (2022).
Google Scholar
Dasgupta, D. et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J. Am. Soc. Nephrol. 25, 2366–2375 (2014).
Google Scholar
Dhayat, N. A. et al. The vitamin D metabolite diagnostic ratio associates with phenotypic traits of idiopathic hypercalciuria. Kidney Int. Rep. 9, 1072–1082 (2024).
Google Scholar
Vezzoli, G. et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J. Am. Soc. Nephrol. 13, 2517–2523 (2002).
Google Scholar
Worcester, E. M., Bergsland, K. J., Gillen, D. L. & Coe, F. L. Evidence for increased renal tubule and parathyroid gland sensitivity to serum calcium in human idiopathic hypercalciuria. Am. J. Physiol. Ren. Physiol. 305, F853–F860 (2013).
Fuster, D. G. & Moe, O. W. Incomplete distal renal tubular acidosis and kidney stones. Adv. Chronic Kidney Dis. 25, 366–374 (2018).
Google Scholar
Moe, O. W. & Preisig, P. A. Dual role of citrate in mammalian urine. Curr. Opin. Nephrol. Hypertens. 15, 419–424 (2006).
Google Scholar
Baggio, B., Gambaro, G., Favaro, S. & Borsatti, A. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease. Nephron 35, 11–14 (1983).
Google Scholar
Laminski, N. A., Meyers, A. M., Kruger, M., Sonnekus, M. I. & Margolius, L. P. Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors. Br. J. Urol. 68, 454–458 (1991).
Google Scholar
Pak, C. Y. et al. Rapid communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate. Kidney Int. 66, 2032–2037 (2004).
Google Scholar
Bazin, D. et al. Hyperoxaluria is related to whewellite and hypercalciuria to weddellite: what happens when crystalline conversion occurs? Comptes Rendus Chim. 19, 1492–1503 (2016).
Bargagli, M., Tio, M. C., Waikar, S. S. & Ferraro, P. M. Dietary oxalate intake and kidney outcomes. Nutrients 12, 2673 (2020).
Google Scholar
Israr, B., Frazier, R. A. & Gordon, M. H. Effects of phytate and minerals on the bioavailability of oxalate from food. Food Chem. 141, 1690–1693 (2013).
Google Scholar
Holmes, R. P., Goodman, H. O. & Assimos, D. G. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 59, 270–276 (2001).
Google Scholar
Baxmann, A. C., De, O. G. M. C. & Heilberg, I. P. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int. 63, 1066–1071 (2003).
Google Scholar
Ferraz, R. R., Tiselius, H. G. & Heilberg, I. P. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int. 66, 676–682 (2004).
Google Scholar
Froeder, L., Arasaki, C. H., Malheiros, C. A., Baxmann, A. C. & Heilberg, I. P. Response to dietary oxalate after bariatric surgery. Clin. J. Am. Soc. Nephrol. 7, 2033–2040 (2012).
Google Scholar
Groothoff, J. W. et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat. Rev. Nephrol. 19, 194–211 (2023).
Google Scholar
Moe, O. W. & Xu, L. H. R. Hyperuricosuric calcium urolithiasis. J. Nephrol. 31, 189–196 (2018).
Google Scholar
Bargagli, M. et al. Urinary lithogenic profile of patients with non-alcoholic fatty liver disease. Nephrol. Dial. Transpl. 38, 2652–2654 (2023).
Sakhaee, K., Adams-Huet, B., Moe, O. W. & Pak, C. Y. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 62, 971–979 (2002).
Google Scholar
Kunlayawutipong, T. et al. Prevalence and risk factors for hyperuricemia and hyperuricosuria in patients with hematologic malignancies. Front. Med. 11, 1343000 (2024).
Rodman, J. S. Struvite stones. Nephron 81, 50–59 (1999).
Google Scholar
Flannigan, R., Choy, W. H., Chew, B. & Lange, D. Renal struvite stones — pathogenesis, microbiology, and management strategies. Nat. Rev. Urol. 11, 333–341 (2014).
Google Scholar
Leaf, D. E., Bukberg, P. R. & Goldfarb, D. S. Laxative abuse, eating disorders, and kidney stones: a case report and review of the literature. Am. J. Kidney Dis. 60, 295–298 (2012).
Google Scholar
Daudon, M., Frochot, V., Bazin, D. & Jungers, P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs 78, 163–201 (2018).
Google Scholar
Maalouf, N. M., Langston, J. P., Van Ness, P. C., Moe, O. W. & Sakhaee, K. Nephrolithiasis in topiramate users. Urol. Res. 39, 303–307 (2011).
Google Scholar
Colliou, E., Mari, A., Delas, A., Delarche, A. & Faguer, S. Oxalate nephropathy following vitamin C intake within intensive care unit. Clin. Nephrol. 88, 354–358 (2017).
Google Scholar
Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. Nat. Rev. Urol. 17, 407–421 (2020).
Google Scholar
Daga, A. et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 93, 204–213 (2018).
Google Scholar
Font-Llitjos, M. et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J. Med. Genet. 42, 58–68 (2005).
Google Scholar
Thomas, K., Wong, K., Withington, J., Bultitude, M. & Doherty, A. Cystinuria — a urologist’s perspective. Nat. Rev. Urol. 11, 270–277 (2014).
Google Scholar
Wu, C. W. et al. Population genetics analysis of SLC3A1 and SLC7A9 revealed the etiology of cystine stone may be more than what our current genetic knowledge can explain. Urolithiasis 51, 101 (2023).
Google Scholar
Crawhall, J. C., Scowen, E. F. & Watts, R. W. Effect of penicillamine on cystinuria. Br. Med. J. 1, 588–590 (1963).
Google Scholar
Chow, G. K. & Streem, S. B. Medical treatment of cystinuria: results of contemporary clinical practice. J. Urol. 156, 1576–1578 (1996).
Google Scholar
Barbey, F. et al. Medical treatment of cystinuria: critical reappraisal of long-term results. J. Urol. 163, 1419–1423 (2000).
Google Scholar
Pak, C. Y., Fuller, C., Sakhaee, K., Zerwekh, J. E. & Adams, B. V. Management of cystine nephrolithiasis with α-mercaptopropionylglycine. J. Urol. 136, 1003–1008 (1986).
Google Scholar
Howles, S. A. et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat. Commun. 10, 5175 (2019).
Google Scholar
Molin, A. et al. CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J. Clin. Endocrinol. Metab. 100, E1343–E1352 (2015).
Google Scholar
Ball, N. et al. 3’ Untranslated region structural elements in CYP24A1 are associated with infantile hypercalcemia type 1. J. Bone Min. Res. 38, 414–426 (2023).
Davidson Peiris, E. & Wusirika, R. A case report of compound heterozygous CYP24A1 mutations leading to nephrolithiasis successfully treated with ketoconazole. Case Rep. Nephrol. Dial. 7, 167–171 (2017).
Google Scholar
Sayers, J. et al. Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole. Clin. Kidney J. 8, 453–455 (2015).
Google Scholar
Schlingmann, K. P. et al. Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J. Am. Soc. Nephrol. 27, 604–614 (2016).
Google Scholar
Gordon, R. J., Li, D., Doyle, D., Zaritsky, J. & Levine, M. A. Digenic heterozygous mutations in SLC34A3 and SLC34A1 cause dominant hypophosphatemic rickets with hypercalciuria. J. Clin. Endocrinol. Metab. 105, 2392–2400 (2020).
Google Scholar
Tieder, M. et al. Hereditary hypophosphatemic rickets with hypercalciuria. N. Engl. J. Med. 312, 611–617 (1985).
Google Scholar
Bergwitz, C. et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am. J. Hum. Genet. 78, 179–192 (2006).
Google Scholar
Colazo, J. M., Reasoner, S. A., Holt, G., Faugere, M. C. M. & Dahir, K. M. Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) presenting with genu valgum deformity: treatment with phosphate supplementation and surgical correction. Case Rep. Endocrinol. 2020, 1047327 (2020).
Google Scholar
Rungroj, N. et al. Distal renal tubular acidosis caused by tryptophan-aspartate repeat domain 72 (WDR72) mutations. Clin. Genet. 94, 409–418 (2018).
Google Scholar
Enerback, S. et al. Acidosis and deafness in patients with recessive mutations in FOXI1. J. Am. Soc. Nephrol. 29, 1041–1048 (2018).
Google Scholar
Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559–2570 (2015).
Google Scholar
Garrelfs, S. F. et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N. Engl. J. Med. 384, 1216–1226 (2021).
Google Scholar
Baum, M. A. et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 103, 207–217 (2023).
Google Scholar
Goldfarb, D. S., Avery, A. R., Beara-Lasic, L., Duncan, G. E. & Goldberg, J. A twin study of genetic influences on nephrolithiasis in women and men. Kidney Int. Rep. 4, 535–540 (2019).
Google Scholar
Hemminki, K. et al. Familial risks in urolithiasis in the population of Sweden. BJU Int. 121, 479–485 (2018).
Google Scholar
Hao, X. et al. Integrative genome-wide analyses identify novel loci associated with kidney stones and provide insights into its genetic architecture. Nat. Commun. 14, 7498 (2023).
Google Scholar
Lovegrove, C. E. et al. Central adiposity increases risk of kidney stone disease through effects on serum calcium concentrations. J. Am. Soc. Nephrol. 34, 1991–2011 (2023).
Google Scholar
Thorleifsson, G. et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat. Genet. 41, 926–930 (2009).
Google Scholar
Oddsson, A. et al. Common and rare variants associated with kidney stones and biochemical traits. Nat. Commun. 6, 7975 (2015).
Google Scholar
Breiderhoff, T. et al. Deletion of claudin-10 (Cldn10) in the thick ascending limb impairs paracellular sodium permeability and leads to hypermagnesemia and nephrocalcinosis. Proc. Natl Acad. Sci. USA 109, 14241–14246 (2012).
Google Scholar
Paranjpe, I. et al. Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis. Kidney Int. 98, 1323–1330 (2020).
Google Scholar
Wang, W. et al. Prospective analysis of incident disease among individuals of diverse ancestries using genetic and conventional risk factors. Preprint at medRxiv (2023).
Pearle, M. S. et al. Medical management of kidney stones: AUA guideline. J. Urol. 192, 316–324 (2014).
Google Scholar
Ljungberg, B. et al. EAU Guidelines, Presented at the EAU Annual Congress Milan 2021 (EAU Guidelines Office, 2021).
Gambaro, G. et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J. Nephrol. 29, 715–734 (2016).
Google Scholar
Williams, J. C. Jr. et al. Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis 49, 1–16 (2021).
Google Scholar
Norman, R. W., Bath, S. S., Robertson, W. G. & Peacock, M. When should patients with symptomatic urinary stone disease be evaluated metabolically? J. Urol. 132, 1137–1139 (1984).
Google Scholar
Edwards, O. M., Bayliss, R. I. & Millen, S. Urinary creatinine excretion as an index of the copleteness of 24-hour urine collections. Lancet 2, 1165–1166 (1969).
Google Scholar
Pak, C. Y., Poindexter, J. R., Adams-Huet, B. & Pearle, M. S. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am. J. Med. 115, 26–32 (2003).
Google Scholar
Daudon, M. & Jungers, P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 64, 245–275 (2004).
Google Scholar
Ferraro, P. M., Taylor, E. N., Gambaro, G. & Curhan, G. C. Dietary and lifestyle risk factors associated with incident kidney stones in men and women. J. Urol. 198, 858–863 (2017).
Google Scholar
Curhan, G. C., Willett, W. C., Rimm, E. B. & Stampfer, M. J. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N. Engl. J. Med. 328, 833–838 (1993).
Google Scholar
Curhan, G. C., Willett, W. C., Speizer, F. E., Spiegelman, D. & Stampfer, M. J. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann. Intern. Med. 126, 497–504 (1997).
Google Scholar
Taylor, E. N., Stampfer, M. J. & Curhan, G. C. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J. Am. Soc. Nephrol. 15, 3225–3232 (2004).
Google Scholar
Parks, J. H. & Coe, F. L. Evidence for durable kidney stone prevention over several decades. BJU Int. 103, 1238–1246 (2009).
Google Scholar
Ferraro, P. M., Taylor, E. N., Gambaro, G. & Curhan, G. C. Soda and other beverages and the risk of kidney stones. Clin. J. Am. Soc. Nephrol. 8, 1389–1395 (2013).
Google Scholar
Phillips, M. J. & Cooke, J. N. Relation between urinary calcium and sodium in patients with idiopathic hypercalciuria. Lancet 1, 1354–1357 (1967).
Google Scholar
Sakhaee, K., Harvey, J. A., Padalino, P. K., Whitson, P. & Pak, C. Y. The potential role of salt abuse on the risk for kidney stone formation. J. Urol. 150, 310–312 (1993).
Google Scholar
Kleeman, C. R., Bohannan, J., Bernstein, D., Ling, S. & Maxwell, M. H. Effect of variations in sodium intake on calcium excretion in normal humans. Proc. Soc. Exp. Biol. Med. 115, 29–32 (1964).
Google Scholar
Nouvenne, A. et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am. J. Clin. Nutr. 91, 565–570 (2010).
Google Scholar
Hess, B., Jost, C., Zipperle, L., Takkinen, R. & Jaeger, P. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol. Dial. Transpl. 13, 2241–2247 (1998).
Taylor, E. N. & Curhan, G. C. Oxalate intake and the risk for nephrolithiasis. J. Am. Soc. Nephrol. 18, 2198–2204 (2007).
Google Scholar
Melton, L. J. 3rd, Crowson, C. S., Khosla, S., Wilson, D. M. & O’Fallon, W. M. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int. 53, 459–464 (1998).
Google Scholar
Worcester, E. M. Stones from bowel disease. Endocrinol. Metab. Clin. North Am. 31, 979–999 (2002).
Google Scholar
Hylander, E., Jarnum, S. & Nielsen, K. Calcium treatment of enteric hyperoxaluria after jejunoileal bypass for morbid obesity. Scand. J. Gastroenterol. 15, 349–352 (1980).
Google Scholar
Taylor, E. N., Fung, T. T. & Curhan, G. C. DASH-style diet associates with reduced risk for kidney stones. J. Am. Soc. Nephrol. 20, 2253–2259 (2009).
Google Scholar
Rodriguez, A., Curhan, G. C., Gambaro, G., Taylor, E. N. & Ferraro, P. M. Mediterranean diet adherence and risk of incident kidney stones. Am. J. Clin. Nutr. 111, 1100–1106 (2020).
Google Scholar
Ferraro, P. M., Mandel, E. I., Curhan, G. C., Gambaro, G. & Taylor, E. N. Dietary protein and potassium, diet–dependent net acid load, and risk of incident kidney stones. Clin. J. Am. Soc. Nephrol. 11, 1834–1844 (2016).
Google Scholar
Brikowski, T. H., Lotan, Y. & Pearle, M. S. Climate-related increase in the prevalence of urolithiasis in the United States. Proc. Natl Acad. Sci. USA 105, 9841–9846 (2008).
Google Scholar
Sasai, F. et al. Climate change and nephrology. Nephrol. Dial. Transpl. 38, 41–48 (2023).
Stamatelou, K. & Goldfarb, D. S. Epidemiology of kidney stones. Healthcare 11, 424 (2023).
Google Scholar
Linder, B. J., Rangel, L. J. & Krambeck, A. E. The effect of work location on urolithiasis in health care professionals. Urolithiasis 41, 327–331 (2013).
Google Scholar
Barcelo, P., Wuhl, O., Servitge, E., Rousaud, A. & Pak, C. Y. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J. Urol. 150, 1761–1764 (1993).
Google Scholar
Ettinger, B. et al. Potassium–magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. 158, 2069–2073 (1997).
Google Scholar
Fink, H. A. et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann. Intern. Med. 158, 535–543 (2013).
Google Scholar
Phillips, R. et al. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst. Rev. 2015, CD010057 (2015).
Google Scholar
Forciea, M. A. & Starkey, M. Prevention of repeated episodes of kidney stones in adults: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 161, P14-9038 (2014).
Hofbauer, J., Hobarth, K., Szabo, N. & Marberger, M. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis-a prospective randomized study. Br. J. Urol. 73, 362–365 (1994).
Google Scholar
Pak, C. Y. et al. Comparison of semi-empirical and computer derived methods for estimating urinary saturation of brushite. J. Urol. 181, 1423–1428 (2009).
Google Scholar
Dhayat, N. A. et al. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. BMC Nephrol. 19, 349 (2018).
Google Scholar
Dhayat, N. A. et al. Hydrochlorothiazide and prevention of kidney-stone recurrence. N. Engl. J. Med. 388, 781–791 (2023).
Google Scholar
Bargagli, M., Anderegg, M. A. & Fuster, D. G. Effects of thiazides and new findings on kidney stones and dysglycemic side effects. Acta Physiol. 240, e14155 (2024).
Christe, A. et al. Hydrochlorothiazide and bone mineral density in patients with kidney stones: a post-hoc analysis of the NOSTONE trial. Clin. J. Am. Soc. Nephrol. 20, 706–718 (2025).
Google Scholar
Pottegard, A. et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J. Intern. Med. 282, 322–331 (2017).
Google Scholar
Pedersen, S. A. et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J. Am. Acad. Dermatol. 78, 673–681 e679 (2018).
Google Scholar
Haisma, M. S. et al. Chronic use of hydrochlorothiazide and risk of skin cancer in Caucasian adults: a PharmLines initiative inception cohort study. Acta Derm. Venereol. 103, adv3933 (2023).
Google Scholar
Borghi, L., Meschi, T., Guerra, A. & Novarini, A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J. Cardiovasc. Pharmacol. 22, S78–S86 (1993).
Google Scholar
Ettinger, B., Citron, J. T., Livermore, B. & Dolman, L. I. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J. Urol. 139, 679–684 (1988).
Google Scholar
Bargagli, M., Trelle, S., Bonny, O. & Fuster, D. G. Thiazides for kidney stone recurrence prevention. Curr. Opin. Nephrol. Hypertens. 33, 427–432 (2024).
Google Scholar
Scoglio, M. et al. Indapamide or chlorthalidone to reduce urine supersaturation for secondary prevention of kidney stones: protocol for a randomised, double-blind, cross-over trial (INDAPACHLOR). BMJ Open 15, e101594 (2025).
Google Scholar
Coe, F. L. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann. Intern. Med. 87, 404–410 (1977).
Google Scholar
Ettinger, B., Tang, A., Citron, J. T., Livermore, B. & Williams, T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N. Engl. J. Med. 315, 1386–1389 (1986).
Google Scholar
Coe, F. L. & Raisen, L. Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet 1, 129–131 (1973).
Google Scholar
Curhan, G. C. & Taylor, E. N. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 73, 489–496 (2008).
Google Scholar
Pak, C. Y., Sakhaee, K. & Fuller, C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 30, 422–428 (1986).
Google Scholar
Kursh, E. D. & Resnick, M. I. Dissolution of uric acid calculi with systemic alkalization. J. Urol. 132, 286–287 (1984).
Google Scholar
Tsaturyan, A. et al. Oral chemolysis is an effective, non-invasive therapy for urinary stones suspected of uric acid content. Urolithiasis 48, 501–507 (2020).
Google Scholar
Assimos, D. et al. Surgical management of stones: American urological association/endourological society guideline, part I. J. Urol. 196, 1153–1160 (2016).
Google Scholar
Geraghty, R. M. et al. Best practice in interventional management of urolithiasis: an update from the European association of urology guidelines panel for urolithiasis 2022. Eur. Urol. Focus 9, 199–208 (2023).
Google Scholar
Sant, G. R., Blaivas, J. G. & Meares, E. M. Jr. Hemiacidrin irrigation in the management of struvite calculi: long-term results. J. Urol. 130, 1048–1050 (1983).
Google Scholar
Griffith, D. P. et al. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur. Urol. 20, 243–247 (1991).
Google Scholar
Jacobs, D., Heimbach, D. & Hesse, A. Chemolysis of struvite stones by acidification of artificial urine – an in vitro study. Scand. J. Urol. Nephrol. 35, 345–349 (2001).
Google Scholar
Poletti, P. A. et al. Low-dose versus standard-dose CT protocol in patients with clinically suspected renal colic. AJR Am. J. Roentgenol. 188, 927–933 (2007).
Google Scholar
Pathan, S. A., Mitra, B. & Cameron, P. A. A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic. Eur. Urol. 73, 583–595 (2018).
Google Scholar
Schmidt, M., Sorensen, H. T. & Pedersen, L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ 362, k3426 (2018).
Google Scholar
Pickard, R. et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet 386, 341–349 (2015).
Google Scholar
Furyk, J. S. et al. Distal ureteric stones and tamsulosin: a double-blind, placebo-controlled, randomized, multicenter trial. Ann. Emerg. Med. 67, 86–95.e82 (2016).
Google Scholar
Sur, R. L. et al. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur. Urol. 67, 959–964 (2015).
Google Scholar
Turk, C. et al. Medical expulsive therapy for ureterolithiasis: the EAU recommendations in 2016. Eur. Urol. 71, 504–507 (2017).
Google Scholar
Ye, Z. et al. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-controlled trial. Eur. Urol. 73, 385–391 (2018).
Google Scholar
Hollingsworth, J. M. et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ 355, i6112 (2016).
Google Scholar
Lovegrove, C. E. et al. Natural history of small asymptomatic kidney and residual stones over a long-term follow-up: systematic review over 25 years. BJU Int. 129, 442–456 (2022).
Google Scholar
Stritt, K. et al. Risk factors of asymptomatic kidney stone passage in adults with recurrent kidney stones. Clin. J. Am. Soc. Nephrol. 19, 1130–1137 (2024).
Google Scholar
Inci, K. et al. Prospective long-term followup of patients with asymptomatic lower pole caliceal stones. J. Urol. 177, 2189–2192 (2007).
Google Scholar
Ong, A. et al. Selection and outcomes for dissolution therapy in uric acid stones: a systematic review of literature. Curr. Urol. Rep. 24, 355–363 (2023).
Google Scholar
EAU Guidelines. Edn. Presented at the EAU Annual Congress, Paris 2024 (EAU Guidelines Office, 2024).
Deng, T. et al. Systematic review and cumulative analysis of the managements for proximal impacted ureteral stones. World J. Urol. 37, 1687–1701 (2019).
Google Scholar
Geraghty, R. et al. Evidence for ureterorenoscopy and laser fragmentation (URSL) for large renal stones in the modern era. Curr. Urol. Rep. 16, 54 (2015).
Google Scholar
Sorensen, M. D. et al. Removal of small, asymptomatic kidney stones and incidence of relapse. N. Engl. J. Med. 387, 506–513 (2022).
Google Scholar
Smith, D. et al. PD47-02 pure RCT 2: clinical and cost-effectiveness of furs and percutaneous nephrolithotomy for lower pole stones 10-25mm. J. Urol. 211, e980 (2024).
Seitz, C. et al. Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. Eur. Urol. 61, 146–158 (2012).
Google Scholar
Evan, A. P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr. Nephrol. 25, 831–841 (2010).
Google Scholar
link